← Trials/Trial dossier/NCT00380276

TerminatedPhase 3

Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol

Open Label Study of the Effect of Daily Treatment With MPC-7869 in Subjects With Dementia of the Alzheimer's Type

Lead sponsor

Myrexis Inc.

Asset

Tarenflurbil

Listed sites

Recruiting sites

Enrollment

1,000

estimated

Study population

Alzheimer’s disease

Key I/E criteria

•Alzheimer's disease•Study partner/caregiver required

Primary endpoint

•Primary Safety

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDMPC-7869-05-009

NCT IDNCT00380276

Timeline

Milestones

Study start2006-09 (month precision)

Study first posted2006-09-25estimated

Last update posted2008-08-05estimated

Study completion2008-12estimated (month precision)

Assets

Drug assets

Tarenflurbil

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age55 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Participation in a previous MPC-7869 randomized protocol

•Have had a diagnosis of probable Alzheimer's disease.

•Men or women ages 55 years or greater and living in the community at the time of enrollment (i.e., not living in a rest home or nursing care facility).

•Signed the subject Informed Consent Form and is willing and able to participate for the duration of the study.

•Female subjects must be surgically sterile or postmenopausal for > 1 year.

•Subjects must have a reliable caregiver who can read, understand and speak English or Spanish

Exclusion criteria

•History or evidence of, active malignancy, except for basal cell carcinoma or squamous cell carcinoma of the skin, within the 24 months prior to entry. Men with prostate cancer may be enrolled at the discretion of the sponsor.

•Chronic or acute renal, hepatic or metabolic disorder.

•Use of any investigational therapy within 30 days, or 5 half-lives, whichever is longer, and/or use of AD immunotherapy prior to screening.

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

1 endpoint

Primary/protocol endpoint

Primary Safety

Time frame:For study duration

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.